Johannesburg Hospital

Running trials

• Recruiting

  A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A

  NCT07830732· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

  NCT06499285· Phase 3· Takeda· Source

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

  NCT06492291· Phase 3· Merck Sharp & Dohme LLC· Source

• Enrolling by invitation

  Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus

  NCT06475742· Phase 3· Viatris Innovation GmbH· Source

• Recruiting

  Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults

  NCT05835479· Phase 2· Mundipharma Research Limited· Source

• Active, not recruiting

  A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

  NCT05904886· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus

  NCT05672576· Phase 3· Viatris Innovation GmbH· Source

• Active, not recruiting

  Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD

  NCT05612035· Phase 2· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

  NCT05654623· Phase 3· Pfizer· Source

• Active, not recruiting

  A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A

  NCT05685238· Phase 3· Novo Nordisk A/S· Source

• Enrolling by invitation

  A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)

  NCT05768386· Phase 4· BioMarin Pharmaceutical· Source

• Recruiting

  A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

  NCT05611801· Phase 3· Pfizer· Source

• Active, not recruiting

  A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors

  NCT05135559· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

  NCT05145127· Phase 3· Pfizer· Source

• Recruiting

  Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program

  NCT04895839· Gabriela Ilie· Source

• Active, not recruiting

  Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

  NCT04821622· Phase 3· Pfizer· Source

• Active, not recruiting

  Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors

  NCT04082429· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors

  NCT04083781· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

  NCT03553836· Phase 3· Merck Sharp & Dohme LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Haemophilia2 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• HIV1 recruiting
• Lupus (SLE)1 recruiting
• Myelodysplastic syndromes1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Terminated

  Safety and Efficacy of FVIIa to Prevent Excessive Bleeding in Hemophilia Patients With Inhibitors Undergoing Major Surgery

  NCT05695391· Phase 3· Laboratoire français de Fractionnement et de Biotechnologies· Source

• Completed

  A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)

  NCT05878938· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Cross-sectional, Observational Study to Characterise Long COVID-19 in an Urban Sample of South African Adults

  NCT05445713· University of Witwatersrand, South Africa· Source

• Completed

  Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

  NCT05405114· Phase 2· Novo Nordisk A/S· Source

• Completed

  A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors

  NCT05306418· Phase 3· Novo Nordisk A/S· Source

• Completed

  Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir

  NCT05169580· Phase 1· Fulcrum Therapeutics· Source

• Completed

  A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors

  NCT05053139· Phase 3· Novo Nordisk A/S· Source

• Completed

  Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

  NCT03938792· Phase 3· Pfizer· Source

• Terminated

  Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5

  NCT03520712· Phase 1/2· BioMarin Pharmaceutical· Source

• Completed

  Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)

  NCT03370913· Phase 3· BioMarin Pharmaceutical· Source

• Completed

  Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

  NCT03025308· Phase 3· Alfasigma S.p.A.· Source